Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Sensei Biotherapeutics Inc
Healthcare
P/NCAV
0.49x
Ticker
SNSE
Exchange
NASDAQ
Country
United States
Close
1.01 $
Mkt Cap
28.2M $
EV
16.9M $
NCAV Burn Rate
38.3%
Current Ratio
11.92
Debt/Equity
0.03
EV/REV
N/Ax
EV/EBIT
-0.5x
EV/FCF
-0.5x
Dilution
-1.1% p.A
Total Net Income
-169.4M $
Cheapness
99.0%
Sensei Biotherapeutics, Inc. is a clinical-stage immuno-oncology company, which is focused on the discovery and development of therapeutics for cancer patients. Through its Tumor Microenvironment Activated biologics (TMAb) platform, the Company develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Its lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation checkpoint selectively within the low pH tumor microenvironment. It is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average